Roy Fleischmann
Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update.
Aletaha D, Kerschbaumer A, Kastrati K, Dejaco C, Dougados M, McInnes I, Sattar N, Stamm T, Takeuchi T, Trauner M, van der Heijde D, Voshaar M, Winthrop K, Ravelli A, Betteridge N, Burmester G, Bijlsma J, Bykerk V, Caporali R, Choy E, Codreanu C, Combe B, Crow M, de Wit M, Emery P, Fleischmann R, Gabay C, Hetland M, Hyrich K, Iagnocco A, Isaacs J, Kremer J, Mariette X, Merkel P, Mysler E, Nash P, Nurmohamed M, Pavelka K, Poór G, Rubbert-Roth A, Schulze-Koops H, Strangfeld A, Tanaka Y, Smolen J. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. Ann Rheum Dis 2022
11.08.2022Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update.
11.08.2022Ann Rheum Dis 2022
Aletaha Daniel, Kerschbaumer Andreas, Kastrati Kastriot, Dejaco Christian, Dougados Maxime, McInnes Iain B, Sattar Naveed, Stamm Tanja, Takeuchi Tsutomu, Trauner Michael, van der Heijde Désirée, Voshaar Marieke, Winthrop Kevin, Ravelli Angelo, Betteridge Neil, Burmester Gerd-Rüdiger, Bijlsma Johannes Wj, Bykerk Vivian, Caporali Roberto, Choy Ernest H S, Codreanu Catalin, Combe Bernard, Crow Mary K, de Wit Maarten, Emery Paul, Fleischmann Roy, Gabay Cem, Hetland Merete Lund, Hyrich Kimme L, Iagnocco Annamaria, Isaacs John D, Kremer Joel M, Mariette Xavier, Merkel Peter A, Mysler Eduardo F, Nash Peter, Nurmohamed Michael T, Pavelka Karel, Poór Gyula, Rubbert-Roth Andrea, Schulze-Koops Hendrik, Strangfeld Anja, Tanaka Yoshiya, Smolen Josef S
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
Genovese M, Meerwein S, Mohamed M, Zhou Y, Zhang Y, Rubbert-Roth A, Hall S, Combe B, Fleischmann R, Pangan A. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet 2018; 391:2513-2524.
18.06.2018Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
18.06.2018Lancet 2018; 391:2513-2524
Genovese Mark C, Meerwein Sebastian, Mohamed Mohamed-Eslam F, Zhou Yijie, Zhang Ying, Rubbert-Roth Andrea, Hall Stephen, Combe Bernard, Fleischmann Roy, Pangan Aileen L